No Data
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $64
Cantor Fitzgerald analyst Kristen Kluska maintains $PTC Therapeutics(PTCT.US)$ with a buy rating, and maintains the target price at $64.According to TipRanks data, the analyst has a success rate of 41
PTC Therapeutics Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ferroptosis Targeting Therapy Market Research & Clinical Trials Insight 2024 Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo, and Tharimmune - ResearchAndMarkets.com
Baird Initiates Coverage On PTC Therapeutics With Outperform Rating, Announces Price Target of $44
Baird Initiates PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $44
Baird analyst Joel Beatty initiates coverage on $PTC Therapeutics(PTCT.US)$ with a buy rating, and sets the target price at $44.According to TipRanks data, the analyst has a success rate of 50.5%